StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) income statement

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.45+0.25 (+1.37%)

Close on Nov 20, 2026Market cap $2.95BP/E –Yield –

See a number that looks wrong?